A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced or Metastatic Breast Cancer
Interventions: DRUG: PF-07220060|DRUG: Fulvestrant|DRUG: Everolimus|DRUG: Exemestane
Sponsor: Pfizer